In view of the numerous studies demonstrating overexpression of EDB/EDA− FN1 in tumorigenic ECM [11,48], it can be speculated that it may also be upregulated in our TGF-β-treated and drug-resistant breast cancer cells. This evidence concerns the gene FN1 and breast carcinoma.